These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31945270)

  • 21. Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease?
    Albayrak F; Gür M; Karataş A; Koca SS; Kısacık B
    Reumatol Clin (Engl Ed); 2024 Mar; 20(3):123-127. PubMed ID: 38494303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining Omalizumab with Another Biotherapy.
    Fougerousse AC; Becherel PA; Pallure V; Boyé T; Reguiai Z; Gabison G; Barthelemy H; Badaoui A; Mahé E; Livideanu CB;
    Acta Derm Venereol; 2019 Apr; 99(4):448-449. PubMed ID: 30723874
    [No Abstract]   [Full Text] [Related]  

  • 23. Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli
    Huang JX; Leong PY; Wei JC
    Ann Rheum Dis; 2022 Nov; 81(11):e226. PubMed ID: 32933918
    [No Abstract]   [Full Text] [Related]  

  • 24. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis.
    van de Kerkhof PCM
    Br J Dermatol; 2021 Nov; 185(5):879. PubMed ID: 34402525
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of guselkumab on ankylosing spondylitis-type pustulotic arthro-osteitis in a patient with palmoplantar pustulosis.
    Yamamoto T
    Dermatol Ther; 2020 Nov; 33(6):e14088. PubMed ID: 33439526
    [No Abstract]   [Full Text] [Related]  

  • 26. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
    Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
    J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-17 for therapy.
    Kurschus FC; Moos S
    J Dermatol Sci; 2017 Sep; 87(3):221-227. PubMed ID: 28633806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials.
    Kvien TK; Conaghan PG; Gossec L; Strand V; Østergaard M; Poddubnyy D; Williams N; Porter B; Shete A; Gilloteau I; Deodhar A
    Arthritis Care Res (Hoboken); 2022 May; 74(5):759-767. PubMed ID: 33227175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy.
    Prince DS; McGuigan LE; McGirr EE
    Int J Rheum Dis; 2014 Feb; 17(2):165-72. PubMed ID: 24576272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis.
    Capkin E; Karkucak M; Yayli S; Aydin Çapkin A; Tosun M
    J Clin Rheumatol; 2011 Aug; 17(5):293-4. PubMed ID: 21808187
    [No Abstract]   [Full Text] [Related]  

  • 31. Unmet needs in the treatment of ankylosing spondylitis: a long-term observational study from a single university center.
    Pelechas E; Kaltsonoudis E; Voulgari PV; Drosos AA
    Rheumatol Int; 2019 Apr; 39(4):663-668. PubMed ID: 30877371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath.
    Williams T; Wadeley A; Bond D; Cavill C; Freeth M; Sengupta R
    Clin Rheumatol; 2020 May; 39(5):1501-1504. PubMed ID: 31989323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple paradoxical adverse events in a patient affected with ankylosing spondylitis treated with TNF blockers.
    Lo Nigro A; Ramonda R; Alaibac M; Modesti V; Punzi L
    Eur J Dermatol; 2011; 21(2):263-4. PubMed ID: 21411412
    [No Abstract]   [Full Text] [Related]  

  • 34. Anti-TNF-α induced paradoxical psoriasis in patients with ankylosing spondylitis: a systematic review.
    Sagonas I; Iliopoulos G; Baraliakos X; Daoussis D
    Clin Exp Rheumatol; 2024 Jan; 42(1):178-184. PubMed ID: 37812484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of adalimumab in a patient with ankylosing spondylitis on peritoneal dialysis.
    Kobak S
    Rheumatol Int; 2012 Jun; 32(6):1785-7. PubMed ID: 20340019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treating to Target(s) With Interleukin-17 Inhibitors.
    Lynde CW; Beecker J; Dutz J; Flanagan C; Guenther LC; Gulliver W; Papp K; Rahman P; Sholter D; Searles GE
    J Cutan Med Surg; 2019; 23(2_suppl):3S-34S. PubMed ID: 30742778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secukinumab: A Review in Ankylosing Spondylitis.
    Blair HA; Dhillon S
    Drugs; 2016 Jul; 76(10):1023-30. PubMed ID: 27255593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secukinumab: first global approval.
    Sanford M; McKeage K
    Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barré syndrome after anti-TNF-α treatment? Case report and literature review.
    Psarelis S; Hajineocli APD; Hadjicosta E; Elliott HSA; Johnson P
    Clin Rheumatol; 2017 May; 36(5):1197-1199. PubMed ID: 28233109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining secukinumab and fingolimod to successfully treat ankylosing spondylitis and multiple sclerosis - A novel approach.
    Nisar MK
    Biologicals; 2019 Jul; 60():93-94. PubMed ID: 31204079
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.